The global Fucosidosis Therapeutics Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Fucosidosis Therapeutics registered a CAGR of 4% in the historical period 2018 to 2022.
Studies state that Fucosidosis is a rare autosomal recessive lysosomal storage disorder characterized by a deficiency of alpha -L-fucosidase. Its estimated frequency is below 1 in 200,000 live births.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 10 Million |
| Anticipated Forecast Value (2033) | US$ 17.91 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Fucosidosis Therapeutics reflected a value of 4% during the historical period, 2018 to 2022.
A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Fucosidosis Therapeutics.
The market's growth is attributed to the factors such as expanding the area of advanced therapies along with gene delivery technologies and has developed progressive competition among key players focused on the commercialization of their therapies. The biotechnology companies are investing in acquisitions, mergers/collaborations, and expansions as key strategies to increase in-house expertise and strengthen product pipelines.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for Fucosidosis Therapeutics. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of fucosidosis is fuelling the market growth. Thus, the market for Fucosidosis Therapeutics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Increased Advancements in R&D technology to Push the Market Growth
Fucosidosis is caused by mutations in a gene known as FUCA1, which provides instructions for the production of an enzyme called alpha-L-fucosidase. Fucosidosis is one of nine identified glycoprotein storage diseases. The massive research and technology for glycoprotein analysis to unravel their structure and function is propelling immense growth. Also the advancing R&D technology and investments into Fucosidosis analysis for drugs therapies vaccines disease progression understanding the biology of glycoprotein and product launches.
Glycoprotein analysis has attracted huge Research and Development investments, subsidization, and reimbursements for glycoprotein-associated antibodies mutations and associated pathway targeting which altogether propels the market growth.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Fucosidosis Therapeutics, less awareness of Fucosidosis disease, and insubstantial treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments is expected to hinder the market growth.
Improvement in healthcare spending propelling the growth of Fucosidosis Therapeutics in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Fucosidosis Therapeutics Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.
Technological Advancements Shaping Landscape for Fucosidosis Therapeutics in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. In August 2022, GlycoNet, a pan-Canadian network of Centers of Excellence centered at UAlberta, received a USD 10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund to continue its mission of researching glycomics for the benefit of human health. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Bone marrow transplantation is an effective therapy to drive the market
The bone marrow transplant procedure is prescribed for the treatment of advanced stages of leukemia, Fucosidosis, Hodgkin, and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia, and other diseases. Increasing awareness, combined with an increase in initiatives run by healthcare practitioners, is majorly responsible for the global growth of the bone marrow transplant market. Therefore, it is anticipated that bone marrow transplant is likely to witness significant growth during the forecast period.
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the Fucosidosis Therapeutics facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target diseases.
Key players in the Fucosidosis Therapeutics Market are Sigma-Aldrich. BD, Enzo Life Sciences, Creative Diagnostics, Thermo Fisher Scientific, Epitope Diagnostics Inc., R&D Systems, QED Bioscience Inc, and ACROBiosystems among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 10 Million |
| Market Value in 2033 | US$ 17.91 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
In 2023, the market is expected to be worth US$ 10 million.
From 2018 to 2022, the global market thrived at a 4% CAGR.
The market is expected to continue growth at a 6% CAGR until 2033.
The Asia Pacific region is scheduled to expand at a swift pace, with a CAGR of 5%.
The market is expected to be around US$ 17.91 million by 2033.
1. Executive Summary | Fucosidosis Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033
5.3.1. Antibiotic Therapy
5.3.2. Fluid Replacement Therapy
5.3.3. Bone Marrow Transplantation
5.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033
6. Global Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Therapy
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Therapy
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Therapy
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Therapy
9.3.3. By End User
9.4. Key Takeaways
10. Europe Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Therapy
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Therapy
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy
11.3.3. By End User
11.4. Key Takeaways
12. MEA Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Therapy
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Fucosidosis Therapeutics Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Therapy
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Therapy
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Therapy
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Therapy
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Therapy
13.5.2.2. By End User
13.6. UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Therapy
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Therapy
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Therapy
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Therapy
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Therapy
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Therapy
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Therapy
13.12.2.2. By End User
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Therapy
13.13.2.2. By End User
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Therapy
13.14.2.2. By End User
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Therapy
13.15.2.2. By End User
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Therapy
13.16.2.2. By End User
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Therapy
13.17.2.2. By End User
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Therapy
13.18.2.2. By End User
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Therapy
13.19.2.2. By End User
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Therapy
13.20.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Therapy
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Baxter
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. B. Braun Melsungen AG
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Fresenius Kabi AG
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. DJ labs
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Lonza Group Ltd
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Sanofi-Aventis LLC
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. AllCells LLC
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Merck Millipore Corporation
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Stemcell Technologies
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. American Type Culture Collection Inc.
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Fucosidosis Therapeutics Market
